denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Blood Journals Studio
Monday, December 9, 2024: 10:00 AM-10:30 AM
Halls G-H - Blood Journals Studio
(San Diego Convention Center)
Moderator:
and
Aaron T. Gerds, MD, MS, Cleveland Clinic Taussig Cancer Institute
Disclosures:
Gerds: AbbVie: Consultancy; GSK: Consultancy; Rain Oncology: Consultancy; PharmaEssentia: Consultancy; Disc Medicine: Consultancy; Agios: Consultancy; BMS: Consultancy.
Panelists:
Andrew S. Weyrich, PhD, Oklahoma Medical Research Foundation
and
Catherine M. Bollard, MD, Children’s National Hospital
Disclosures:
Bollard: Sobi: Honoraria; Nextimmune: Current equity holder in publicly-traded company; Repertoire Immune Medicines: Current equity holder in private company; Cabaletta Bio: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Mana Tx: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Catamaran Bio: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Minovia Tx Ltd: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees.
Dr. Aaron Gerds, Editor-in-Chief of ASH Clinical News, interviews Blood Advances Editor-in-Chief Dr. Catherine Bollard and Deputy Editor Andrew Weyrich on the topic of peer review.
See more of: Blood Journals Studio